VANCOUVER, May 31, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced that effective this week, Allan Cleiren has been appointed as Chief Operational Officer (COO).
Based in Edmonton, Alberta, Mr. Cleiren will be responsible for synergistic integration of both domestic and international acquisitions, assessing future opportunities for further expansion, while keeping a healthy balance between growth and protection of shareholder value, and optimization of the organization's structure and processes with a view of carrying growth while achieving increased operational efficiencies.
Mr. Cleiren has nearly three decades of leadership experience in finance and operations management with both privately and publicly held companies in the life sciences, insurance, rail, construction, oil and gas service, and other sectors. Through various senior positions, he has held responsibility for all aspects of operations, including manufacturing, logistics, human resources, IT, and marketing. As a senior financial executive, Mr. Cleiren also has considerable experience in M&A and restructuring. Throughout his career, Mr. Cleiren's focus has been on achieving operational excellence and efficiency, contributing to significant revenue and profitability growth.
Most recently, Mr. Cleiren was COO with Jardine Lloyd Thompson Canada Inc. (JLT), one of the world's leading providers of insurance, reinsurance and employee benefits related advice, brokerage and associated services. Prior to joining JLT, he served as Executive Vice President and formerly CFO for Universal Rail Systems Inc, and as Senior Vice President of Operations and CFO for Afexa Life Sciences. He is a member of the Board of Directors of Universal Rail Services Inc., Metalogic Inspection Services Inc., and is Chair of the Board for the Alberta Automobile Insurance Rate Board.
Mr. Cleiren is a Chartered Professional Accountant (CPA, CA), holds a Bachelor of Commerce from the University of Alberta, and has a Diploma in Management Sciences from the Grant MacEwan College in Alberta. Mr. Cleiren also holds a ICD.D designation through the Institute of Corporate Directors.
"As a rapidly growing organization, with multiple production facilities and a large number of corporate initiatives to manage, excellence in operations is of paramount importance to us, and we believe Allan is the right person to take on this important role at Aurora," said Terry Booth, CEO. "With Aurora expanding both within Canada and internationally, and the growth of our employee base, we needed a multi-talented, multi-faceted operations professional to further enhance our management team. With his strong and diverse background, Allan will be able to ensure that our execution continues to meet and exceed our extremely high internal standards."
"I am delighted to be taking on this new role at the most innovative company in an exciting sector that, while maturing rapidly, continues to evolve at an extremely rapid pace," added Mr. Cleiren. "Aurora has a strong and differentiated vision, excellent leadership team, and is well on its way to becoming one of the world's leading cannabis companies. I look forward to be working with Terry and the rest of the team to further establish the Aurora Standard as the benchmark in this industry."
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, as well as owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ("EU"), based in Germany. Aurora's common shares trade on the TSX-V under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.
For further information: For Aurora Cannabis Inc.: Cam Battley, Executive Vice President, +1.905.864.5525, email@example.com, www.auroramj.com; Marc Lakmaaker, NATIONAL Equicom, firstname.lastname@example.org, +1.416.848.1397